8-K: BioNexus Gene Lab Corp. Granted Second Extension to Regain Nasdaq Compliance

BioNexus Gene Lab Corp. has received a second 180-day extension from Nasdaq to regain compliance with the minimum bid price rule.

Summary

• BioNexus Gene Lab Corp. was previously notified by Nasdaq on November 6, 2023, that it did not meet the minimum bid price requirement of $1.00 per share.
• The company was initially given 180 days, until May 6, 2024, to regain compliance.
• BioNexus requested an additional 180-day extension and informed Nasdaq of its intention to potentially perform a reverse stock split to cure the deficiency.
• On May 8, 2024, Nasdaq granted the company an additional 180-day extension, until November 4, 2024, to regain compliance.
• The company will regain compliance if its stock price closes at or above $1.00 for at least ten consecutive business days during this extension period.
• If the company fails to regain compliance during this period, Nasdaq may delist the stock, but the company can request a hearing to appeal the decision.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the company's failure to maintain the minimum bid price and the risk of delisting, despite the extension.

Positives

• The company has been granted a second extension, providing more time to regain compliance.
• The company has a clear path to regain compliance by maintaining a $1.00 share price for ten consecutive days.
• The company has the option to request a hearing if delisting is initiated, providing an opportunity to appeal.

Negatives

• The company has failed to maintain the minimum bid price of $1.00 per share for an extended period.
• There is no guarantee that the company will be able to regain compliance within the extended period.
• The possibility of delisting from the Nasdaq Capital Market remains a significant risk.

Risks

• The company may not be able to increase its share price to $1.00 for ten consecutive days.
• The company may need to implement a reverse stock split, which could negatively impact shareholder value.
• Delisting from Nasdaq could significantly reduce the company's access to capital and investor confidence.
• The company's ability to operate effectively may be impacted by the uncertainty surrounding its listing status.

Future Outlook

The company intends to regain compliance with Nasdaq listing rules, potentially through a reverse stock split, but there is no guarantee of success.

Management Comments

• The company intends to cure the deficiency during any second compliance period extension by effecting a reverse stock split, if necessary.
• The company will use all reasonable efforts to achieve compliance with Rule 5550(a)(2).

Industry Context

Many small-cap biotech companies face challenges in maintaining share price compliance, especially in volatile market conditions. This situation is not unique to BioNexus Gene Lab Corp.

Comparison to Industry Standards

• Many small-cap biotech companies on the Nasdaq face similar challenges with maintaining minimum bid prices.
• Companies like Athersys and Ocugen have also faced delisting notices and have had to implement reverse stock splits or other measures to regain compliance.
• The 180-day extension period is a standard procedure for companies facing non-compliance issues on Nasdaq.

Stakeholder Impact

• Shareholders face the risk of further share price decline and potential delisting.
• Employees may experience uncertainty regarding the company's future.
• The company's ability to raise capital may be negatively impacted.

Next Steps

• The company must increase its share price to at least $1.00 for ten consecutive business days before November 4, 2024.
• The company may implement a reverse stock split to increase its share price.
• The company may request a hearing before the Nasdaq Hearings Panel if delisting is initiated.

Key Dates

Keywords

Nasdaq, compliance, delisting, minimum bid price, reverse stock split, extension, BGLC